Common Stock, $0.001 par value per share
- Symbol
- HTFL
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
HTFLNASDAQEQUITYCurrent
Item 2.02 Results of Operations and Financial Condition . On August 13, 2026, Heartflow, Inc. issued a press release regarding its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Press release in this filing
Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance →Heartflow’s technology is redefining precision diagnostic testing and management for coronary artery disease (CAD) through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,800 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by American College of Cardiology and American Heart Association (ACC/AHA) guidelines and supported by more than 625 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 800,000 patients worldwide. 1 Key benefits include:
Heartflow, Inc. · 8-K · Filed 2026-08-13
EX-99.1 2 htfl-20260813xex99_1.htm EX-99.1 Exhibit 991 20260813 Exhibit 99.1 Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance SAN FRANCISCO - August 13, 2026 - Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Highlights Total revenue of $64.1 million, a 48% increase year-over-year Gross margin of 83.0%, non-GAAP gross margin of 83.3% Net operating loss of $17.9 million; non-GAAP net operating loss of $7.9 million 2026 Annual Guidance Total revenue of $246 million to $250 million (approximately 40% to 42% growth year-over-year), compared to previous guidance of $228 million to $232 million (approximately 29% to 32% growth year-over-year) Non-GAAP gross margin of approximately 82%, compared to previous guidance of approximately 81% "The second quarter reflects the growing strength of Heartflow's category leadership and unique AI technology platform for identifying, diagnosing, managing and treating coronary artery disease," said John Farquhar, Pr…
Open exhibit ↗